AddedRisk Factors
•in California, the Private Attorneys General Act, or PAGA, which empowers employees to bring representative actions for alleged violations of the California Labor Code. As a California-based employer, we face heightened legal and financial exposure under PAGA, including exposure related to scale and complexity of class actions, statutory PAGA penalties, and compliance and defense burden of such claims;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
oncology diagnostics company based in Tel Aviv, Israel, with global operations. Doing business internationally involves a number of risks, including:
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Furthermore, the C2i Acquisition included acquiring personal data that may originate from, be processed in, or be transferred to and from, Israel, the EU and other jurisdictions. Our ability to process, use and transfer such personal data may
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
Some patients may decide not to use our tests because of price, all or part of which may be payable directly by the patient if the patient’s insurer denies reimbursement in full or in part. There is a growing trend among insurers to shift more of the cost of healthcare to patients in the form of higher co-payments or premiums, putting patients in the position of having to pay more
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Prior to its acquisition, C2i was not required to maintain an internal control infrastructure that would meet the standards of a public company, including the requirements of the Sarbanes-Oxley Act of 2002. Beginning in 2024, we began to integrate C2i into our internal control structures and implemented additional internal controls where needed. As we continue to integrate and improve the operations of C2i and other acquired businesses, we may need to implement additional controls. The costs that we may incur to implement such controls and procedures may be substantial and we could encounter unexpected delays and challenges in this implementation. In addition, we may discover significant deficiencies or material weaknesses in the quality of an acquired business’s financial and disclosure controls and procedures;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•We have experienced quality, regulatory or manufacturing irregularities and challenges in connection with our Marseille, France facility, and we may continue to rely on NanoString as a sole source provider;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The revenue that we have experienced in our biopharma and other services business may not continue to transpire.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
In 2023 and 2024, we experienced significant declines in biopharma and other services revenue as a result of reductions in customer projects, extended sales cycles and overall spending constraints across the industry in the U.S. and internationally. The success and continuity of our biopharma services business depends in part on our ability to identify and successfully negotiate with appropriate pharma partners. We cannot guarantee that our existing partnerships will be successful or that we may identify further appropriate pharma partners and other business relationships. If our existing partners terminate their agreements with us, we may experience disruptions to our business and revenues. Further, depending on the success of our biopharma and other services, including their ability to generate revenues, we may reassess our pursuit of certain non-core businesses from time to time, which may include pausing or discontinuing certain non-core businesses, any of which may have a material adverse effect on our business and financial condition.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
On May 6, 2024, the FDA issued a final rule under 21 CFR Part 809 to make explicit that IVD products are devices under the Federal Food, Drug, and Cosmetic Act, removing much of the FDA's historical enforcement discretion for most LDTs. In conjunction with this final rule, the FDA will phase out its general enforcement discretion approach for LDTs in five stages over a four-year period, and implement targeted enforcement discretion policies for certain categories of IVDs manufactured by a laboratory. Each stage of the proposed phaseout period would subject LDTs to a set of regulatory requirements. For example, the first stage of the phaseout would require LDT developers to comply with medical device reporting requirements, complaint
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
handling and correction and removal reporting requirements within one year after the FDA publishes the final rule. LDTs that are considered higher risk IVDs would be subject to premarket review requirements within three and a half years, and LDTs that are considered moderate or low risk IVDs would be subject to premarket submission requirements beginning four years after the FDA publishes the final rule.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Hampshire, New Jersey, Oregon, Rhode Island, Tennessee, Texas, Utah, and Virginia have each enacted laws similar to the CCPA/CPRA. The multiple layers of privacy law within the United States could increase our potential liability, increase our compliance costs, and adversely affect our business.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Changes to Internal Revenue Code Section 174 under the 2017 Tax Cuts and Jobs Act went into effect in 2022. The revised code no longer permits a deduction for research and development expenditures in the tax year that such costs are incurred. Instead, such costs must be capitalized and amortized over five or 15 years for U.S. and foreign costs, respectively. The new rules will change the utilization of our NOLs and it is uncertain whether the new rules will be repealed or modified in the future.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our business or financial results may be adversely impacted by uncertain economic conditions, including: regional conflicts globally, turmoil in the global banking and finance system, adverse changes in interest rates, foreign currency exchange rates, tax laws or tax rates; inflation; a recession; the impact of disease outbreak; government shutdown; contraction
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
Some of these items are unique to these suppliers and vendors and their inability to provide us with reagents that perform to specifications, could negatively impact our ability to provide timely response and reports to our customers and, as a result, may materially impact our ability to generate revenue.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many several EU member states have adopted national “Sunshine Acts” which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the United States, on medical device manufacturers.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We Our high complexity clinical labs that design, develop and manufacture our laboratory developed tests are subject to CLIA, the Clinical Laboratory Improvement Amendment (CLIA) regulations, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, and the licensor may fail to prevent infringement by third parties, or the licensed patents or other rights could be found to be invalid or unenforceable.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Following the lead of California, several other states, including Colorado, Connecticut, Delaware, Indiana, Iowa, Kentucky, Maryland, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, Oregon, Rhode Island, Tennessee, Texas, Utah, and Virginia have each enacted laws similar to the CCPA/CPRA.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further, we cannot be certain that such agreements have been entered into with all relevant parties, or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Canada Of the $561.9 million of U.S. federal net operating loss carryforwards carryforwards, $57.5 million will begin to expire in 2034, 2036 while for French purposes, the net operating losses remainder will carryforward indefinitely.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The first Protecting Access to Medicare Act of 2014, or PAMA, data reporting period for CPT 81546 (Afirma GSC), CPT 81542 (Decipher Prostate), and CPT 0016U (Decipher Bladder) under the current triennial data reporting process is expected to occur between May 1 through July 31, 2026 based on the data collection period of January and March 2029. 1 through June 30, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Under the IVDR, if If any RUO material product is integrated into an IVD, IVD MD, it must be fully validated assessed and documented as part of the device. device and comply with the IVDR.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We cannot predict whether these revisions will delay future This guidance has extended the timelines for development of new LCDs and may result in impeded coverage for our test products, which could have a material negative impact on revenue.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The revised SCCs are not to be relied on for data transfers to non-EEA entities subject to the GDPR, and we are waiting for further guidance on valid mechanisms for data transfers from the EEA to such entities.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If our general strategy of seeking incremental growth through acquisitions and collaborations is not successful, or if we do not successfully integrate companies or assets that we acquire into our business, our prospects and financial condition will may suffer.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
An RUO material product on its own may not be used for clinical diagnostic purposes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
For most many IVD MDs, the manufacturer used to self-declare the conformity of its products with the essential requirements of the IVDD.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
These bodies have all issued subpoenas and other requests for information to conduct investigations of, and commenced civil and criminal litigation actions against, healthcare companies based on financial arrangements with health-care providers (including physicians and labs), regulatory compliance, product promotional practices and documentation, and coding and billing practices.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty penalties associated with the violation, including civil and criminal penalties, damages and fines, we could be required to refund payments received by us, and we could be required to curtail or cease our operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In the above table, Medicare Advantage plans are included with their associated private payer amounts and Medicare amounts do not include Medicare Advantage.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We test our intangible assets and other long-lived assets for impairment on an annual basis and we perform regular reviews to determine if any event has occurred that may indicate that the carrying values of our intangible assets with finite lives and other long-lived assets are impaired. If indicators of impairment exist, we assess the recoverability of the affected assets by determining whether their carrying amounts exceed their undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value exceeds the fair value. Factors that may indicate potential impairment include significant changes in the ability of an asset to generate positive cash flows and the pattern of utilization of a particular asset.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
expense, selling and marketing expense, research and development expense, and cost of revenue based on the headcount and employee location.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On July 16, 2025, the Marseille Commercial Court published a decision approving the divestiture of the contract manufacturing portion of our French subsidiary, Veracyte SAS, to Helio Diagnostics SAS, effective August 1, 2025. The remaining assets of Veracyte SAS will be managed by the judicial administrator until such time that the Marseille Commercial Court appoints a judicial liquidator to solely initiate and manage final liquidation proceedings. Effective August 1, 2025, we ceased to have a controlling interest in Veracyte SAS. As we began judicial restructuring proceedings affecting Veracyte SAS with the Marseille Commercial Court in the second quarter of 2025, we evaluated whether the associated assets of Veracyte SAS were impaired. We concluded, during the second quarter of 2025, that the long-lived assets of the Veracyte SAS asset group were not recoverable. As a result, we recorded a $20.5 million non-cash impairment charge during the year ended December 31, 2025 primarily related to the Company's right-of-use assets; property, plant, and equipment; and certain tax credits.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, the One Big Beautiful Bill Act, or the OBBBA, was signed into law. The legislation includes a broad range of tax reform provisions affecting businesses including, but not limited to, the reinstatement of 100% bonus depreciation, immediate expensing of domestic research and development costs, and revisions to the U.S. taxation of profits derived from international operations. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We have assessed the effects of the new tax legislation, including immediate expensing of domestic research and development expenditures, and the results have been reflected in the Form 10-K for the year ended December 31, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Non-cancelable purchase commitments totaled approximately $44.0 million as of December 31, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
We incur a significant amount of expenses related to activities to secure clinical trial results in support of our testing and product development portfolio and on-market tests, as well as clinical validation and utilization studies. We also deploy state-of-the-art and costly genomic technologies in our discovery experiments, and our spending on these technologies may vary substantially from quarter to quarter. The timing of these research and development activities is difficult to predict, as is the timing of clinical trial enrollments and sample acquisitions. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses can affect our financial results. We conduct clinical studies to validate our new products, as well as on-going clinical studies to further the published evidence to support our commercialized tests. As these studies are initiated, start-up costs for each site can be significant and concentrated in a specific quarter. Spending on research and development, for both experiments and studies, may vary significantly by quarter depending on the timing of these various expenses.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
significant expense as we invest in the continued development of our innovation engine, early-stage products including our MRD tests, required clinical studies and the development of current IVD tests.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
For biopharmaceutical and other revenue, we develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if they can be satisfied at a point in time or over time, and we measure the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amounts to be included in the transaction price. Milestone payments that are not within either party’s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of milestones that are within either party’s control, such as operational developmental milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Revisions to our estimate of the transaction price may also result in negative revenues and earnings in the period of adjustment.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
During the second half of 2024, we strategically entered into longer purchase commitments to stabilize our supply chain, manage inventory risk, and secure optimal pricing for essential supplies. The increase in supplier purchase commitments also reflects the growth in our testing volume. As a result, non-cancelable purchase commitments totaled approximately $43.2 million as of December 31, 2024, compared to approximately $19.4 million at December 31, 2023.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Pursuant to the Agreement and Plan of Merger, dated as of January 5, 2024, by and among the Company, C2i, Canary Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company, Veracyte Diagnostics, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company, and Fortis Advisors LLC, as the C2i securityholders’ agent, or the Merger Agreement, we may be required to pay to certain noteholders of C2i up to an additional $20.0 million in cash or shares of our common stock, at our election, upon the achievement of certain milestones. During the three months ended December 31, 2024, one of the milestones was achieved resulting the payment of $5.0 million. As of December 31, 2024, we expect to achieve a portion or all of the remaining milestones contained in the Merger Agreement within the next 12 months, requiring payments totaling approximately $16.6 million.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
As part of our agreement to acquire the exclusive global diagnostic license to the nCounter Analysis System, we may be required to pay up to an additional $10.0 million in cash, contingent upon first achievement or occurrence, by us or on our behalf, of the commercial launch of the first, second and third diagnostic tests for use on the nCounter multiplex analysis system. As of December 31, 2024, the achievement of one of the milestones is forecasted to occur within the next 12 months, requiring payments totaling $3.5 million.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
Cash used as a result of changes in operating assets and liabilities was $16.4 $2.3 million, primarily comprising an increase in accounts receivable of $4.5 million, a decrease in accrued liabilities of $3.9 million, a decrease in operating lease liability of $3.4 $2.5 million, an increase in prepaid expense and other current assets of $2.1 million, an increase in supplies and inventory of $3.0 $2.9 million, a decrease in accounts payable of $1.0 million, and an increase in other assets accounts receivable of $3.0 $0.7 million, partially offset by an increase in accrued liabilities of $6.3 million and a decrease in prepaid expense and other current assets of $1.4 $0.5 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by used in financing activities for the year ended December 31, 2023 2025 was $2.8 $4.2 million, consisting of $9.6 $18.3 million in tax payments during the period related to the vesting of restricted stock units granted to employees, partially offset by $14.1 million in proceeds from the exercise of options to purchase our common stock and purchase of stock under our Employee Stock Purchase Plan, or ESPP, partially offset by $6.7 million in tax payments during the period related to the vesting of restricted stock units granted to employees. ESPP.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by used in investing activities for the year ended December 31, 2023 2025 was $15.1 $9.2 million consisting of $25.1 $9.7 million used in the acquisition of property and equipment, partially offset by net proceeds of $150.0 million from the purchase and maturity of short-term investments, offset by $10.0 million used in the acquisition of property and equipment. investments.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Biopharmaceutical and other revenue decreased by $5.8 $3.5 million for the year ended December 31, 2024 2025 compared to 2023 driven primarily by 2024, due to the reduction of customer projects decrease in the business conducted in France given overall spending constraints across the industry. restructuring proceedings affecting Veracyte SAS in August 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Other income, net, increased $0.4 $0.8 million for the year ended December 31, 2024 2025 compared to 2023, 2024, primarily due to an increase of $3.8 $6.0 million due to foreign currency revaluation and an increase of $1.6 million of interest and dividend income, partially offset by an increased a loss of $2.8 $6.7 million related due to unrealized foreign currency gain(loss). the deconsolidation of Veracyte SAS.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our cost of biopharmaceutical and other revenue are the consists of costs of performing activities under arrangements that require us to perform license or provide access to our assets or laboratory testing services, as well as costs incurred in providing contracted research and development, contract testing services, commercialization, development and contract manufacturing and development. activities.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In addition to the these development of new product candidates, activities, we believe these also perform clinical evidence studies which are critical to gaining clinician adoption of new products and our tests, driving favorable coverage decisions by payors payers, as well as gaining guideline inclusion for such products. tests.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
This was primarily due to a $92.4 $74.2 million increase in testing revenue driven by a 23% 19% volume increase and a 4% average selling price increase, $0.7 million increase in our product revenue, partially offset by a $5.8 $3.5 million decrease in our Biopharmaceutical and other revenue, as well as a $1.9 million decrease in our product revenue.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Inventory consists of raw materials consumed in the contract manufacturing process as well as finished and semi-finished components goods used in the assembly of diagnostic kits related to product sales. sales as well as raw materials consumed in the contract manufacturing process.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Other income (loss), net consists primarily of interest income from our cash held in interest bearing accounts, realized and unrealized gains and losses on foreign currency transactions, and and, prior to the restructuring proceedings affecting Veracyte SAS in August 2025, French research tax credits. credits, as well as loss on deconsolidation of Veracyte SAS.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Years Ended December 31, 2025 2024 2023 2022 Net cash provided by operating activities $ 136,307 $ 75,096 $ 44,222 $ 7,535 Net cash (used in) provided by investing activities (9,209) (56,275) 15,112 Net cash (used in) investing activities (56,275) 15,112 (29,387) Net cash provided by financing activities (4,222) 4,904 2,837 3,494
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer, either on its own or together with other resources that are readily available to the customer, and is separately
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
Additionally, primarily outside of the United States, we provide IVD tests to patients through distribution to laboratories and hospitals that can perform the tests locally.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new